Overview

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Status:
Recruiting

Trial end date:
2025-12-08

Target enrollment:

Participant gender:

Summary

A Phase 2 multi-center, open-label, single arm study of nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas who have not received prior treatment with mTOR inhibitors

Phase:

Phase 2

Details

Lead Sponsor:

Aadi Bioscience, Inc.

Treatments:

Sirolimus